The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19 DOI Creative Commons
Jie Wang, Qian Zhang, Hongmei Wang

et al.

Frontiers in Bioscience-Landmark, Journal Year: 2022, Volume and Issue: 27(5)

Published: May 13, 2022

Coronavirus disease 2019 (COVID-19), which broke out at the end of 2019, is a global pandemic and seriously threatens human health. Vaccination most effective way to prevent control COVID-19. At present, more than 13 COVID-19 vaccines have been urgently authorized for use, but emergence severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has brought unprecedented challenges protective efficiency these vaccines. In particular, recent Delta Omicron variants, are rapidly spreading worldwide, may bring many medical systems. Interestingly, previous studies shown that Bacillus Calmette-Guerin (BCG) vaccine used tuberculosis can induce non-specific trained immunity, protecting against infectious diseases caused by viruses. Therefore, there hypothesis BCG plays an essential role in reducing incidence, severity, hospitalization, mortality enhancing protection vaccine. To confirm this hypothesis, 56 clinical trials conducted globally assess BCG’s effectiveness infection. Herein, review discussed immunity induced its underlying mechanisms summarised latest research progress preventing COVID-19, especially ongoing trials. We hope will provide new strategies fighting

Language: Английский

Nanovaccines: A game changing approach in the fight against infectious diseases DOI Open Access

Priyanka Choudhary,

Mai Abdel Haleem Abusalah, Hitesh Chopra

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 167, P. 115597 - 115597

Published: Sept. 30, 2023

The field of nanotechnology has revolutionised global attempts to prevent, treat, and eradicate infectious diseases in the foreseen future. Nanovaccines have proven be a valuable pawn this novel technology. are made up nanoparticles that associated with or prepared components can stimulate host's immune system. In addition their delivery capabilities, nanocarriers been demonstrated possess intrinsic adjuvant properties, working as cell stimulators. Thus, nanovaccines potential promote rapid well long-lasting humoral cellular immunity. several possible benefits, including site-specific antigen delivery, increased bioavailability, diminished adverse effect profile. To avail these nanoparticle-based vaccines being developed, virus-like particles, liposomes, polymeric nanoparticles, nanogels, lipid emulsion vaccines, exomes, inorganic nanoparticles. Inspired by distinctive researchers on development for variety applications, such cancer immunotherapy diseases. Although few challenges still need overcome, modulation nanoparticle pharmacokinetics avoid elimination from bloodstream reticuloendothelial system, future prospects technology also assuring, multiple options personalised needle-free formulations, combination promising candidates.

Language: Английский

Citations

75
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic DOI Creative Commons
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama

et al.

Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 682 - 682

Published: March 17, 2023

We are currently approaching three years since the beginning of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2 has caused extensive disruptions in everyday life, public health, and global economy. Thus far, vaccine worked better than expected against virus. During pandemic, we experienced several things, such as virus its pathogenesis, clinical manifestations, treatments; emerging variants; different vaccines; development processes. This review describes how each been developed approved with help modern technology. also discuss critical milestones during process. Several lessons were learned from countries two research, development, trials, vaccination. The process will to fight next

Language: Английский

Citations

66
Chitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines DOI Creative Commons

Xiaochen Gong,

Yuan Gao, Jianhong Shu

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(11), P. 1906 - 1906

Published: Nov. 11, 2022

With the support of modern biotechnology, vaccine technology continues to iterate. The safety and efficacy vaccines are some most important areas development in field. As a natural substance, chitosan is widely used numerous fields—such as immune stimulation, drug delivery, wound healing, antibacterial procedures—due its good biocompatibility, low toxicity, biodegradability, adhesion. Chitosan-based nanoparticles (NPs) have attracted extensive attention with respect adjuvants delivery systems due their excellent properties, which can effectively enhance responses. Here, we list classifications mechanisms action adjuvants. At same time, preparation methods chitosan, NPs, mechanism system introduced. applications NPs protein nucleic acid also This paper reviewed latest research progress chitosan-based adjuvant systems.

Language: Английский

Citations

60
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena DOI Creative Commons
Vivek P. Chavda, Rajashri Bezbaruah,

Mansi Athalye

et al.

Viruses, Journal Year: 2022, Volume and Issue: 14(4), P. 759 - 759

Published: April 6, 2022

The “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” is the third member of human (CoV) that held accountable for current “coronavirus disease 2019 (COVID-19)” pandemic. In past two decades, world has witnessed emergence other similar CoVs, namely SARS-CoV in 2002 and MERS-CoV 2013. extent spread these earlier versions was relatively low comparison to SARS-CoV-2. Despite having numerous reports inclined towards zoonotic origin virus, one cannot simply sideline fact no animal originated CoV thus far identified considered initial edition SARS-CoV-2; however, under-sampling diverse variety coronaviruses remains a concern. Vaccines are proved be an effective tool bringing end such devastating Many vaccine platforms explored same but this review paper, we will discuss potential replicating viral vectors as carriers

Language: Английский

Citations

55
Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach DOI Creative Commons
Asim Azhar, Wajihul Hasan Khan, Parvez Anwar Khan

et al.

Journal of Infection and Public Health, Journal Year: 2022, Volume and Issue: 15(4), P. 466 - 479

Published: Feb. 18, 2022

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is yet to be controlled worldwide, especially in India. second wave of disease 2019 (COVID-19) led panic and confusion India, owing the overwhelming number population that fell prey this highly infectious virus recent times. In COVID-19, patients had fight both opportunistic infections triggered fungi bacteria. Repeated use steroids, antibiotics, oxygen masks during management severely critically ill COVID-19 nurtured such as mucormycosis. Despite mucormycosis being a decades-old disease, it has gained notice its widespread occurrence throughout Instances are usually unearthed immunocompromised individuals inhalation filamentous fungi, either from natural environment or through supportive care units. outbreak been seen cause secondary infection grows along with treatment COVID-19. Furthermore, comorbidities diabetes were more likely have co-infection because their challenged immune systems' inability it. hype, still remains neglected least studied, which predominantly due all focus on diagnostics, vaccine, therapeutic research. review, we emphasize mainly association patients. We also present molecular mechanism for better understanding fungal who recently infected SARS-CoV-2. Better pathogens, immediate diagnosis, crucial patients, high mortalities recorded co-infected despite recovery

Language: Английский

Citations

40
Lessons from the COVID-19 Pandemic: Promoting Vaccination and Public Health Resilience, a Narrative Review DOI Creative Commons
Flavia Pennisi, Cristina Genovese, Vincenza Gianfredi

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(8), P. 891 - 891

Published: Aug. 7, 2024

The COVID-19 pandemic has underscored the critical importance of adaptable and resilient public health systems capable rapid response to emerging crises. This paper synthesizes lessons learned from vaccination campaign explores strategies enhance vaccine uptake in post-pandemic era. Key challenges identified include logistical, economic, sociocultural, policy dimensions that impact efforts, particularly low-resource settings. analysis highlights need for supply chains, effective communication, community engagement, equitable access healthcare resources. development deployment mRNA vaccines exemplify potential innovative technologies, though trust acceptance remain crucial. Strategies such as partnerships with local leaders, tailored messaging, integration digital tools are essential combating hesitancy. By applying these insights, future campaigns can be more efficient, equitable, resilient, ultimately improving outcomes globally. aims inform practice, ensuring evidence based context specific, thus better preparing challenges.

Language: Английский

Citations

11
mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy DOI Creative Commons
Dariush Haghmorad, Majid Eslami,

Niloufar Orooji

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13

Published: March 12, 2025

The advent of mRNA vaccines, accelerated by the global response to COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss development, current applications, and prospects vaccines for both prevention treatment infectious diseases oncology. By leveraging capacity encode antigens within host cells directly, provide versatile scalable platform suitable addressing broad spectrum pathogens tumor-specific antigens. We highlight recent advancements design, innovative delivery mechanisms, ongoing clinical trials, with particular emphasis on their efficacy combating diseases, such as COVID-19, Zika, influenza, well emerging potential cancer immunotherapy. also address critical challenges, including stability, optimization immune responses, broader issue accessibility. Finally, review strategies advancing next-generation aim overcoming limitations technology enhancing preventive therapeutic approaches oncological diseases.

Language: Английский

Citations

1
COVID-19 Booster Vaccination Hesitancy in the United States: A Multi-Theory-Model (MTM)-Based National Assessment DOI Creative Commons
Kavita Batra, Manoj Sharma, Chia‐Liang Dai

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(5), P. 758 - 758

Published: May 11, 2022

Background: Despite the availability of COVID-19 vaccines and proven benefits vaccinations outweighing potential risks, hesitancy to accept additional doses remains a persistent problem. Therefore, purpose study was investigate hesitancy, confidence, literacy, role multi-theory model (MTM) constructs in booster uptake. Methods: This cross-sectional utilized 52-item psychometric valid web-based survey conducted during month October 2021 recruit nationally representative sample U.S. adults. Univariate, bivariate, multivariate statistical tests were used analyze data. Results: Among hesitant group (n = 209, 41.7%), significantly larger proportion respondents unvaccinated with primary series (43.5% vs. 11%, p < 0.001), among 18−44 years age (51.2% 31.8%, single or never married (33.0% 24.3%, 0.04), had lower education some high school (6.2% 2.4%, 0.03), identified themselves as Republicans (31.6% 20.5%, 0.01). The mean scores vaccine 19% odds behavioral confidence than their non-hesitant counterparts (adjusted ratio 0.81, 95% CI: 0.71−0.92). Conclusions: findings this underscore need raising public awareness through effective multi-theory-model-based communication campaigns.

Language: Английский

Citations

38
Perception of COVID-19 Booster Dose Vaccine among Healthcare Workers in India and Saudi Arabia DOI Open Access

Sajith Vellappally,

Sachin Naik, Omar Alsadon

et al.

International Journal of Environmental Research and Public Health, Journal Year: 2022, Volume and Issue: 19(15), P. 8942 - 8942

Published: July 22, 2022

Background: COVID-19 vaccines were made available to the public by end of 2020. However, little is known about booster dose (CBD) vaccine perception among healthcare workers (HCW) worldwide. The present study aims assess CBD in India and Saudi Arabia (SA). Methods: A cross-sectional was conducted HCWs two countries, SA. Data gathered through use a self-administered questionnaire. convenience sampling technique utilized collect data. Results: total 833 HCW responses collected from with 530 participants 303 SA responding Among them, 16% 33% unwilling take (p < 0.005). primary reasons for not being willing concerns whether would be effective (32%) probable long-term side effects (31%). Concerns knowing enough vaccination (30%) possibility (28%) Regression analysis showed that males, urban residents, post-graduates more CBD. Conclusion: There good some hesitancy receiving both countries. introduction personalized education, risk communication, deliberate policy could help reduce number people who are shot.

Language: Английский

Citations

33
The effect of BCG vaccination on infection and antibody levels against SARS-CoV-2—The results of ProBCG: a multicenter randomized clinical trial in Brazil DOI Creative Commons
Ana Paula Santos, Guilherme Loureiro Werneck, Ana Paula Razal Dalvi

et al.

International Journal of Infectious Diseases, Journal Year: 2023, Volume and Issue: 130, P. 8 - 16

Published: Feb. 24, 2023

Evatuate if Bacillus Calmette-Guérin (BCG) vaccine could be used as a tool against SARS-CoV-2 based on the concept of trained immunity.A multicenter, double-blinded, randomized clinical trial recruited health care workers (HCWs) in Brazil. The incidence rates COVID-19, manifestations, absenteeism, and adverse events among HCWs receiving BCG (Moreau or Moscow strains) placebo were compared. vaccine-mediated immune response before after implementing specific vaccines for COVID-19 (CoronaVac COVISHIELD) was analyzed. Cox proportional hazard linear mixed effect modeling used.A total 264 volunteers included analysis (BCG = 134 130). group presented cumulative 0.75% vs 0.52% BCG. Moreau strain also higher rate (1.60% × 0.22%). did not show protective ratio COVID-19. In addition, log (immunoglobulin G) level increase group, whether participants had but without statistical significance.Our results suggest that has tendency protection immunoglobulin G levels than placebo. registered at https://clinicaltrials.gov/ (NCT04659941).

Language: Английский

Citations

19